Potassium 2-(1-hydroxypenty1)-benzoate (
dl-PHPB) is a new
drug candidate for treatment of
ischemic stroke with antiplatelet effect. In this study, we investigated the mechanisms of
dl-PHPB in inhibiting platelet aggregation. The
ADP-activated P2Y1-Gq-PLC and P2Y12-Gi-AC pathways were observed, respectively.
Intravenous injection of
dl-PHPB (1.3, 3.9, 12.9 mg/kg) significantly inhibited
ADP-,
collagen-, and
arachidonic acid-induced rat platelet aggregation in a dose-dependent manner, and
dl-PHPB had a relatively more potent inhibitory effect on
ADP-induced rat platelet aggregation than other agonists.
Dl-PHPB also showed a decreased expression of CD62P (a marker for platelet activation) mediated by
ADP. Both
dl-PHPB and
ticlopidine (
P2Y12 receptor antagonist) decreased cytoplasmic Ca(2+) concentration. But,
dl-PHPB did not reverse the inhibition of PGE1-induced platelet cAMP formation by
ADP, which was different from
ticlopidine. Further,
dl-PHPB instead of
ticlopidine showed increasing
phospholipase C-β phosphorylation (ser(1105)). The
m-3M3FBS, a
phospholipase C activator, attenuated the inhibitory effect of
dl-PHPB on
ADP-induced platelet aggregation and enhanced IP1 accumulation in rat platelets.
Dl-PHPB decreased IP1 accumulation induced by
ADP but had no effect on IP1 level enhanced by
m-3M3FBS. Our results suggest that
dl-PHPB has a potent antiplatelet effect, which is mainly through blockade of P2Y1 receptor-PLC-IP3 pathway and decreasing cytoplasmic
calcium.